Publications
Search our bibliography using the filters on the right-hand side.
Displaying 151 through 164 of 164 publications.
Skip to main content
Lewis SA. A practical walkthrough of an epro design kickoff. Benefits and challenges with epro: outcomes and endpoints as we emerge from the long age of paper methods. Presented at the Drug Information Association conference workshop; 2005.
Schmidt RA, Ackerman SJ, Newstead GM, Quam JP, Mordin MM, Anastassopoulos K, Nishikawa RM. Comparative feature analysis of computed radiography for mammography (CRM) soft copy display vs. crm hard copy film: an observer performance study. Poster presented at the 90th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2004.
Eaton SC, Mangel AW, Hollis KA, Ameen VZ, Hamm LR, Andrews EB, Williams RL, Cook SF. Symptoms of diarrhea-predominant or alternating IBS: an exploratory analysis. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.
Rothman KJ. A potential bias in safety evaluation during open-label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(5):295-8.
Quam JP, Ackerman SJ, Mordin MM, Bassett LW. Conspicuity and characterization of findings on computed radiography for mammography vs. screen-film mammography: results from a prospective clinical trial. Poster presented at the 89th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2003.
Trump DL, Wilding G, Miller K, Small E, Soulie P, Trachtenberg J, Raabe N, Heyes AE, Das-Gupta A. Pilot trials of ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisolone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. Presented at the American Urology Association; April 2003. Chicago, IL.
Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.
McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003 Jan 1;21(15):1069-79.
Fehnel SE, McLeod LD, Brandman J, Arbit DI, McLaughlin-Miley CJ, Coombs JH, Martin AR, Girman CJ. Responsiveness of the acne-specific quality of life questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res. 2002 Dec 1;11(8):809-16.
Menter A, Gottlieb A, Griffiths C, Mordin MM. Health-related quality of life impact of weekly intravenous or intramuscular alefacept in patients with psoriasis: results from two randomized, placebo-controlled phase III trials. Poster presented at the Annual Meeting of the American Academy of Dermatology; February 2002.
Neighbors DM, Candrilli SD. Concomitant medication costing using clinical trial data: a case study. Presented at the 2000 ISPOR 5th Annual International Meeting; May 2000. Arlington, VA.
Steffensen FH, Sorensen HT, Gillman MW, Rothman KJ, Sabroe S, Fischer P, Olsen J. Low birth weight and preterm delivery as risk factors for asthma and atopic dermatitis in young adult males. Epidemiology. 2000 Mar;11(2):185-8.
Sorensen HT, Steffensen FH, Olsen J, Sabroe S, Gillman MW, Rothman KJ, Fischer P. Long-term follow-up of cognitive outcome after breech presentation at birth. Epidemiology. 1999 Sep 1;10(5):554-6.
McKenna SP, Koppeschaar HPF, Zelissen PMJ, Snel YEM, Whalley D, Doward LC. The impact of replacement gh on the quality of life of patients: results of a clinical trial in the Netherlands. Poster presented at the 22nd International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism; October 18, 1996. Vienna, Austria.